Buy Rating Affirmed for Third Harmonic Bio Amidst Promising Clinical Developments and Market Prospects
Third Harmonic Bio Analyst Ratings
Buy Rating Justified by Third Harmonic Bio's Promising Drug THB335 and Swift Clinical Advancements
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Madrigal Pharmaceuticals (MDGL) and Third Harmonic Bio, Inc. (THRD)
Third Harmonic Bio Analyst Ratings
Stifel Initiates Coverage On Third Harmonic Bio With Buy Rating, Announces Price Target of $23
Third Harmonic Bio Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Third Harmonic Bio, Inc. (THRD), Treace Medical Concepts (TMCI)
Morgan Stanley Maintains Equal-Weight on Third Harmonic Bio, Raises Price Target to $7
Third Harmonic Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Third Harmonic Bio, Inc. (THRD) and Verve Therapeutics (VERV)
LifeSci Capital Upgrades Third Harmonic Bio, Inc. (THRD) to a Buy
LifeSci Capital Sticks to Its Hold Rating for Third Harmonic Bio, Inc. (THRD)
LifeSci Capital Keeps Their Hold Rating on Third Harmonic Bio, Inc. (THRD)
Third Harmonic Bio Analyst Ratings